Summary Tumour-inhibitory effects of a new antagonist of growth hormone-releasing hormone (GH-RH), MZ-4-71, were evaluated in nude mice bearing androgen-independent human prostate cancer cell lines DU-145 and PC-3 and in Copenhagen rats implanted with Dunning R-3327 AT-1 prostatic adenocarcinoma. After 6 weeks of therapy, the tumour volume in nude mice with DU-1 45 prostate cancers treated with 40 ,ug day-' MZ-4-71 was significantly decreased to 37 ± 13 mm3 (P < 0.01) compared with controls that measured 194 ± 35 mm3. A similar inhibition of tumour growth was obtained in nude mice bearing PC-3 cancers, in which the treatment with MZ-4-71 for 4 weeks diminished the tumour volume to 1 19 ± 35 mm3 compared with 397 ± 115 mm3 for control animals. Therapy with MZ-4-71 also significantly decreased weights of PC-3 and DU-145 tumours and increased tumour doubling time. Serum levels of GH and IGF-I were significantly decreased in animals treated with GH-RH antagonist. In PC-3 tumour tissue, the levels of IGF-I and IGF-II were reduced to non-detectable values after therapy with MZ-4-71. The growth of Dunning R-3327 AT-1 tumours in rats was also significantly inhibited after 3 weeks of treatment with 100 gg of MZ-4-71 day-' i.p. as shown by a reduction in tumour volume and weight (both P-values < 0.05). Specific high-affinity binding sites for IGF-I were found on the membranes of DU-145, PC-3 and Dunning R-3327 AT-1 tumours. Our results indicate that GH-RH antagonist MZ-4-71 suppresses growth of PC-3, DU-145 and Dunning AT-I androgen-independent prostate cancers, through diminution of GH release and the resulting decrease in the secretion of hepatic IGF-I, or through mechanisms involving a lowering of tumour IGF-I levels and possibly an inhibition of tumour IGF-I and IGF-Il production. GH-RH antagonists could be considered for further development for the therapy of prostate cancer, especially after the relapse.
Carcinoma of the prostate is the most common malignant tumour in men. It is expected that in 1996 approximately 317 000 new cases of prostate cancer will be diagnosed in the US and that about 41 000 deaths will occur from this disease (Parker et al, 1996) . In spite of refinements in surgical techniques (Walsh et al, 1994) and improvement of clinical outcome after radiotherapy (Garnick, 1993) , many patients experience a recurrence. According to Lu-Yao et al (1996) , 34.9% of patients studied after radical prostatectomy needed additional cancer therapy within 5 years of initial surgery. In addition to these highly selected patients with clinically localized prostate cancer at initial presentation, there is a large group of men with advanced stages of the disease at the time of primary diagnosis. Medical or surgical castration is the only established therapy for local recurrence or advanced prostate cancer (Schally et al, 1990 ) with an effective first-line response rate of 70-80% (Sharifi et al, 1990) . However, all hormonal therapies aimed at androgen deprivation can only provide a remission, and most patients with advanced prostatic carcinoma will relapse in 18-36 months. The suppression of androgen-independent prostate cancer is a major oncological challenge, and new therapeutic approaches must be developed.
The PC-3 prostate cancer cell line was originally isolated from a metastasis of a human prostatic adenocarcinoma to bone (Kaighn et al, 1979) . PC-3 cells show a reduced dependence upon serum for growth and cannot be stimulated by androgens (Kaighn et al, 1979) . The DU-145 cell line, derived from a human prostate adenocarcinoma metastatic to the brain is also androgen independent (Stone et al, 1978) . These two cell lines can be xenografted into nude mice. Dunning R 3327 AT-1, a subline derived from the rat Dunning prostate cancer, is an anaplastic, hormone-insensitive tumour, transplantable into rats (Isaacs et al, 1978) . PC-3, DU-145 and Dunning R-3327 AT-I cell lines are valuable models for investigating biological tumour behaviour and the effect of new anticancer drugs on androgen-independent prostate carcinoma.
The prostate is a hormone-sensitive organ, primarily under the control of the pituitary-gonadal axis (Schally et al, 1990; Reubi et al, 1995) . However, some regulatory factors other than androgens have been identified, among them hormones, such as luteinizing hormone-releasing hormone (LH-RH), GH, somatostatin and bombesin-like peptides and growth factors, including epidermal growth factor (EGF), transforming growth factors-a and -P (TGF-a, TGF-,3), IGF-I and IGF-II (Davies and Eaton, 1991; Schally et al, 1990; Reubi et al, 1995; Angelloz-Nicoud and Binoux, 1995; Reiter et al, 1995) . These substances can directly or indirectly regulate the function and growth of the prostate, especially after malignant transformation. Synthesis of IGF-1 is induced primarily by GH but, in addition, growth factors like EGF and proto-oncogenes like c-myb may be involved (Pietrzkowski et al, 1993) . IGF-I is synthesized and secreted mostly by the liver, but also by other tissues, such as lung and kidney (Froesch et al, 1985) . Various cancer cells are likewise able to produce and secrete insulin-like growth factors (Macaulay, 1992) , among them PC-3 and DU-145 prostate cancer cell lines (Pietrzkowski et al, 1993) . Type I IGF receptors (IGFRs) have been shown on membranes of DU-145 and PC-3 cells (Pietrzkowski et al, 1993) . Furthermore, there is some evidence that IGF might be responsible for the progression of prostate cancer in the advanced stages. Consequently, the blocking of the GH-IGF axis might lead to improvement in the treatment of advanced, androgen-independent prostate cancer.
Recently, various potent GH-RH antagonists have been synthesized in our laboratory, including [Ibull, 6, Abu"3, Nle27] hGH-RH(1-28)Agm (MZ-4-71) (Zarandi et al, 1994) . This antagonist has previously been shown to inhibit growth of human osteosarcomas (Pinski et al, 1995) and human small-and nonsmall-cell lung cancers in athymic nude mice (Pinski et al, 1996) . In the present study, we investigated the effect of the GH-RH antagonist MZ-4-71 on the growth of the hormone-independent prostate cancer cell lines DU-145 and PC-3 xenografted into nude mice, and rat Dunning R-3327 AT-1 tumours transplanted into Copenhagen rats. In addition, we examined the effect of this antagonist on the proliferation of DU-145 and PC-3 cells in vitro.
MATERIALS AND METHODS Peptide and reagents
The GH-RH antagonist MZ-4-7 1, ([Ibu'', D-Arg2, Phe(4-Cl)6, Abu", Nle'7] hGH-RH(1-28)Agm) was synthesized by solidphase methods and purified in our laboratory (Zarandi et al, 1994 
Method of tissue extraction
Tumour and liver tissue concentrations of IGF-I and IGF-II were determined by an adaptation of the methods described previously (D'Ercole et al, 1984) . The tissue was cut in small slices and homogenized in 5 ml of I M acetic acid 1 g-I tissue using Ultra Turrax homogenizer at 4°C. The homogenate was centrifuged at 2000 x g for 20 min at 4°C. The supernatant was collected and the pellet was washed and recentrifuged. The supernatants were combined, lyophilized and reconstituted in 0.1 M phosphate buffer. The BIO-RAD protein assay kit (Hercules, CA, USA) was used for protein determination.
Radioimmunoassays of GH, IGF-I and IGF-II
Serum GH was determined using materials provided by Dr AF Parlow (Pituitary Hormones and Antisera Center, Torrance, CA, USA; mouse GH reference preparation AFP10783B, mouse GH antigen AFP10783B and anti-rat GH-RIA-5/AFP-411S). All serum and reconstituted tissue samples for IGF-I and IGF-II determination were extracted by a modified acid-ethanol cryoprecipitation method described previously (Daughaday et al, 1980; Breier et al, 1991) . This method eliminates most of the IGF binding proteins, which can interfere in the radioimmunoassay (RIA). The extracted IGF-I was measured by RIA using IGF-I (88-G4, from Genentech, San Francisco, CA, USA) for standard in the range of 2-500 pg per tube and for iodination using the standard chloramine-T method. Antibody UB3-189 and UB2-495 (a gift from Dr Underwood and J van Wyk) obtained from NIDDK was used at the final dilution of 1:10 000 and 1: 14 000 in the RIA. IGF-II was measured using human recombinant IGF-II (Bachem California, Torrance, CA, USA) in the range of 2-500 pg per tube. IGF-II was iodinated by lactoperoxidase method and purified by reverse-phase high-performance liquid chromatography (HPLC) using a Vydac C 18 column. For the assay, Amano monoclonal antibody generated against rat IGF-II (10 ,ug ml-') was used at a final dilution of 1:14 285 (Amano Enzymes USA, Troy, VA, USA). This antibody cross-reacts 100% with human and rat IGF-II and 10% with human IGF-I (Tanaka et al, 1989) .
Receptor assay
Measurement of receptors for IGF-I in the membranes of DU-145, PC-3 and Dunning R-3327 AT-1 tumours was performed as described previously (Pinski et al, 1995) . The LIGAND PC computerized curve-fitting program of Munson and Rodbard (1980) was used to determine the types of receptor binding, dissociation constant (Kd) values and the maximal binding capacity (Bmax) of receptors.
Growth in serum-free medium
For the MTT assay, cells were seeded into 96-well microplates (Falcon, Lincoln Park, NJ, USA) in serum-free medium. The medium contained RPMI-1640 (Gibco), 0.5% bovine serum albumin (BSA), 1 mm pyruvate and 1 ,UM ferrous sulphate (all from Sigma).
MTT assay
This assay is based on a method described by Plumb et al (1989) . Briefly, cells were seeded into 96-well microplates and cultured for 18 h. MZ-4-71 was added to the medium in final concentrations of 10-7-10-5 M. Control cultures received serum-free medium alone. After 72 h of culture, the medium was removed and 200 gl of serum-free medium containing 80 ,ug of MTT [3, (4, dimethylthiazol-2yl)-2,5-diphenyl tetrazolium bromide; Sigma] was added. The microplates were incubated for 4 h at 37°C in darkness. The medium was removed, cells were washed with RPMI-1640 medium, then 200 jl of dimethyl sulphoxide (DMSO; Sigma) was added, followed by 25 jil of Sorensen's glycine buffer (0.1 M glycine plus 0.1 M sodium chloride, pH 10.5). After a brief mixing, the plates were read at 540 nm on the plate reader (Beckman, Palo Alto, CA, USA). Results were calculated as % TIC, where T = optical density (OD540nm) of treated cultures (serum-free medium plus and C = OD540nm of control cultures (serum-free medium alone) x 100.
Statistical methods
All data are expressed as means ± s.e.m., and statistical analyses of the tumour data were performed using Duncan's new multiple range test (Steel and Torrie, 1976) . All P-values are based on twosided hypothesis testing.
RESULTS

Effects of GH-RH antagonist MZ-4-71 on growth of DU-145 and PC-3 tumours in nude mice
At the end of the experiments, there were no significant differences in body weights between the treated and the untreated groups except that mice with PC-3 tumours, given MZ-4-71, weighed more than the control animals (Table 1) . In experiment I, after 4 weeks of treatment, the volume of DU-145 prostate carcinomas in the group receiving MZ-4-71 was significantly reduced to 30.9 ± 11.1 mm3 compared with the control group (91.2 ± 12.3 mm3), corresponding to a 66% decrease in tumour volume (Figure lA). After 6 weeks, the final tumour volume and weight were significantly (P < 0.01) diminished in animals treated with MZ-4-71 to 37.6 ± 13.5 mm3 and 4.0 ± 1.0 mg, respectively, compared with controls (194.2 ± 55.4 mm3 and 18.6 ± 3.0 mg). Tumour doubling time in mice receiving MZ-4-71 was extended to 56.6 days from 13.4 days calculated for control animals.
In experiment II, therapy with MZ-4-7 1 also inhibited the growth of PC-3 prostate cancer tumours ( Figure IB) . After 4 weeks of therapy, when the experiment was terminated, mean tumour volume and weight were significantly (P < 0.01) reduced in animals receiving GH-RH antagonist MZ-4-71 to 119.9 ± 35.3 mm3 and 13.1 ± 3.6 mg compared with those for control animals, which were 397.5 ± 115.6 mm3 and 56.1 ± 8.6 mg respectively. Tumour doubling time was prolonged by MZ-4-71 to 17.8 ± 3 days from 8.7 ± 1.3 days found for control animals (P < 0.05).
Effect of GH-RH antagonist MZ-4-71 on Dunning R-3327 AT-1 tumours in rats
In experiment III, MZ-4-7 1 effectively suppressed growth of the very fast proliferating Dunning R-3327 AT-I tumour in rats.
After 3 weeks of therapy, tumour volume was 6153 ± 1267 mm3 in the group treated with GH-RH antagonist compared with 11 005 ± 1338 mm3 for control animals (P < 0.05) (Figure 2 ).
The therapy with MZ-4-71 also significantly reduced tumour weight but did not affect body weight. The effects of the treatment on final tumour volume, body and tumour weight and tumour doubling time for rats bearing Dunning R-3327 AT-1 prostate carcinoma are shown in Table 1 . compared with control animals (21.27 ± 5.34 ng ml-'). The GH-RH antagonist also significantly decreased serum IGF-I levels to 134.5 ± 0.7 ng ml-', compared with 172.5 ± 1 ng ml-' in control animals. Serum levels of IGF-ll at the end of the treatment period with MZ-4-71 were similar to those in control animals ( Table 2) . In animals bearing PC-3 tumours, serum growth hormone was decreased by 46% in the MZ-4-71-treated group (31.1 ± 1.9 ng ml-' vs 57.1 ± 3.6 ng ml-' for control animals; P < 0.05). Serum IGF-I was also significantly lower in the animals treated with GH-RH antagonist (93.8 ± 13.6 ng ml-') compared with 135.6 ± 10.6 ng ml-' for control animals, whereas serum IGF-II levels were similar (Table 2) . Therapy with MZ-4-71 reduced the IGF-I and IGF-II concentrations in PC-3 tumour tissue below the detection range of the relevant RIA, whereas control tumour tissue showed 145.36 ± 25.22 pg IGF-I 100 jg-' protein and 189.11 ± 31.44 pg IGF-ll 100 .g-' protein (Table 3) . After therapy with MZ-4-71, levels of IGF-II in liver tissue of nude mice bearing PC-3 tumours were not significantly changed, while those of IGF-I were reduced from 44.58 ± 4.5 to 32.55 ± 2.5 pg 100 jig-' protein (P < 0.05)( Table 3) . IGF-I and IGF-II measurements in rat serum from the animals implanted with Dunning R-3327AT-1 tumours could not be performed because of an accidental loss of samples. tumours (Kd = 0.82 ± 0.11 nM). A significant (P < 0.01) increase in binding capacity of IGF-I receptors was observed after treatment with MZ-4-71 (Bmax = 244.6 + 4.9 fmol mg-' membrane protein vs 151.4 ± 5.85 fmol mg-' membrane protein for control animals) (Table 4 ).
Effect of GH-RH
In PC-3 tumour membranes, specific high-affinity binding sites for IGF were also demonstrated. In control tumours, the dissociation constant was calculated to be Kd = 0.69 ± 0.25 nm and maximal binding capacity Bmax = 90.6 ± 12.9 fmol mg-' membrane protein. After therapy with MZ-4-71, B max of the receptors for IGF-I was significantly augmented; i.e. the number of high-affinity receptor sites was increased to 164.4 ± 3.8 fmol mg-1 membrane protein (Table 4) .
Receptor assays on control rat Dunning R-3327-AT-1 tumours showed high-affinity binding sites for IGF-I (Kd = 0.49 ± 0.14 nM). After 3 weeks of treatment with MZ-4-71, there were no significant changes in the concentration and the affinity of the receptors for IGF-I.
Effects of IGF-I and GH-RH antagonist MZ-4-71 on cell proliferation in vitro
In order to evaluate the stimulatory effect of IGF-I and a possible anti-proliferative activity of the GH-RH antagonist MZ-4-71 on DU-145 and PC-3 cell lines in vitro, the MTT assay was used. However, IGF-I at concentrations of 5-25 ng ml-l did not significantly stimulate the proliferation of either cell line and the stimulation was calculated to be only between 8% and 23%. At a relatively high concentration of 10-5 M, GH-RH antagonist MZ-4-71 decreased the proliferation of DU-145 cells by 63.3% compared with the control (P < 0.05), but lower concentrations of the antagonist only non-significantly blunted growth of DU-145 cells. The PC-3 prostate cancer cell line was not affected by , even at concentrations up to I0-5 M (data not shown).
DISCUSSION
There are few therapeutic options available for the therapy of androgen-independent prostate carcinoma. Suramin, a polysulphonated naphthylurea, primarily used in the treatment of parasitic disorders, produces a clinical response rate of approximately 50% in patients with advanced, androgen-independent prostate cancers (Eisenberger et al, 1993) . The actual mechanism of anti-tumour activity of this drug is unknown, but inhibition of binding of various growth factors to their receptors has been suggested as a possibility. Pollak and Richard (1990) blocked the IGF-I-stimulated proliferation of human osteosarcoma cells with suramin, reinforcing the hypothesis of the possible importance of the GH-IGF-I axis in tumour growth stimulation. Human DU-145 and PC-3 prostate cancer cell lines and rat Dunning R-3327 AT-1 prostate carcinoma are suitable models of the advanced, hormoneinsensitive stage of this malignant disease. Our work shows that GH-RH antagonist MZ-4-71 effectively inhibits the growth of DU-145 and PC-3 prostate cancer in nude mice and prolongs tumour doubling time. Our findings on this GH-RH antagonist are in accordance with previous studies on osteosarcoma cell lines (Pinski et al, 1995) and human small-cell and non-small-cell lung carcinomas (Pinski et al, 1996) , in which MZ-4-71 effectively inhibited tumour growth. GH receptors have been identified in a large number of tissues, among them the human prostate and PC-3 prostate cancer cell line (Reiter et al, 1995) . Treatment with MZ-4-7 1 significantly reduced serum GH levels in nude mice bearing DU-145 or PC-3 prostate carcinomas. This suggests that some of the inhibitory effect of the GH-RH antagonist might be attributed to the reduction in serum GH concentration. GH directly regulates the IGF-I synthesis in the liver and other organs (Macaulay, 1992) . A significant fall in GH levels, induced by the GH-RH antagonists, could, through mechanisms involving suppression of IGFs, be of major importance for the inhibition of tumour growth. Measurements of serum IGF levels can be affected by the presence of IGF-binding proteins, but our assays were performed after acid-ethanol cryoprecipitation extraction (Breier et al, 1991; Daughaday et al, 1980) . Recently, Lee et al (1996) examined acid-ethanol extraction and acid-chromatography procedure for IGF and reported that the results were nearly identical. Only small amounts of residual small molecular weight IGF-binding proteins were found in the acid-ethanol extraction (Lee et al, 1996) . Crawford et al (1992) also compared various extraction methods for IGF-I in rat serum, including acid-ethanol extraction with HPLC method. Their results show that IGF-I levels found after acid-ethanol extraction are similar to those obtained by HPLC. Crawford et al (1992) also indicated that the acid-ethanol extraction method of Daughaday et al (1980) , originally validated for human serum, is also satisfactory for use with rat serum. Our work shows that, in nude mice treated with the GH-RH antagonist MZ-4-71, serum IGF-I levels were significantly lower compared with control animals. There are conflicting data about the role of the IGF system in the biology of DU-145 and PC-3 human prostate cancer cell lines. Pietrzkowski et al (1993) have reported that DU-145 and PC-3 cells maintain an autocrine production of IGF-I. They showed that the concentration of autocrine IGF-I was sufficient to autophosphorylate the IGF-I receptor and to sustain growth in serum-free cell culture conditions. This autocrine loop, in which produced IGF-I activates its receptors, is at variance with a study by Iwamura et al (1993) , who found IGF-I receptors in both cell lines, but could not detect autocrine production of IGF-I. Similarly, Figueroa et al (1995) and Angelloz-Nicoud and Binoux (1995) found an expression of IGF-II and IGF receptors in DU-145 and PC-3 prostate cancer cells respectively, but failed to detect mRNA for IGF-I. Their data suggest an IGF-II-dependent autocrine growth loop.
In our in vitro experiments, addition of 5-25 ng ml-' IGF-I had no stimulatory effect on proliferation in DU-145 and PC-3 cell lines. This is in accord with Pietrzkowski et al (1993) , who showed that substantial amounts of IGF-I are secreted by the respective cell lines into the medium and that further exogenous IGF-I had no additional effect on cell proliferation. The determination of GH-RH and GH receptors in prostate cancer and other tumours is the subject of our ongoing investigations. The lack of a dose-dependent effect of GH-RH antagonist MZ-4-7 1 on the proliferation of DU-145 and PC-3 prostate cancer cells in vitro suggests that no receptors for GH-RH were present on the membranes of these cells or that these cell lines could have undergone changes in GH-RH receptor content during long-term passages in cell cultures. Examples of the loss of peptide receptors after multiple passages are well known . Thus, in a study on human colonic and gastric tumour cells, Watson et al (1988) found that the newly established cell lines were stimulated by pentagastrin at passage 2, but long-established cell lines did not respond to pentagastrin, indicating that tumour cell response to hormones was decreased or lost during in vitro cultures. These phenomena might explain the differences between the extent of tumour growth inhibition in vivo and in vitro obtained with our peptides. The doses of MZ-4-71 used in vitro to achieve an inhibition of proliferation of DU-145 tumours were very high. The concentration of MZ-4-71 in the blood of nude mice given a subcutaneous injection of this antagonist at a dose of 20 gg per animal is approximately 20 pM (Pinski et al, 1995) , i.e. 500 000 times lower than the dose of MZ-4-71 required to inhibit the growth of DU-145 cells in vitro (10 gM). It would also be intriguing to speculate whether a possible relationship might exist between GH and GH-RH receptors and IGF-I and IGF-II production in tumours, since both these growth factors appear to be involved in PC-3 and DU-145 cell proliferation (Pietrzkowski et al, 1993; Angelloz-Nicoud and Binoux, 1995; Figueroa et al, 1995) . However, in the absence of this information, the inhibitory effect of MZ-4-7 1 on the growth of androgen-independent prostatic cancers in vivo observed in our study may be attributed to the suppression of pituitary GH and hepatic IGF-I secretion and only tentatively to unknown mechanisms leading to an inhibition of autocrine/paracrine IGF-I and IGF-II production and/or lowering of tumour IGF-I and IGF-II levels. In our study, tissue concentrations of IGF-I and -II were measured in the liver and tumours of treated and untreated PC-3 tumour-bearing animals. In the liver, IGF-I levels were significantly blunted in the MZ-4-7 1-treated group, whereas IGF-II levels did not change. On the other hand, in PC-3 tumours, both IGF-I and IGF-1I fell below the detection range of the specific RIAs after the treatment with MZ-4-7 1.
Our findings, which show the presence of high-affinity binding sites for IGF-I in membranes of both PC-3 and DU-145 tumours, are in agreement with results previously reported by other groups (Pietrzkowski et al, 1993; Iwamura et al, 1993; Figueroa et al, 1995) . IGF-I and IGF-II bind with different affinities to type 1 IGF receptor, which is thought to mediate the biological effects of both ligands through tyrosine kinase-type activity (Cohen et al, 1994) . We observed that chronic treatment of nude mice with the GH-RH antagonists produced an increase of the concentration of IGF-I receptors on both tumours. This phenomenon might be an indication of a compensatory up-regulation of IGF-I receptor synthesis caused by suppression of the endocrine or local production of IGF-I.
Dunning R-3327 AT-I is a fast growing anaplastic, androgenindependent rat prostate cancer derived from the rat Dunning-H tumour (Isaacs et al, 1978) . In this model, the tumour growth was also decreased in the GH-RH antagonist-treated group. The mechanism of action of GH-RH antagonist in this prostate cancer is unclear. It has been demonstrated that Dunning R-3327 tumours express GH receptors (Sinowatz et al, 1991) . Thus, the decrease in the levels of GH could contribute to the inhibition of tumours. Tumour growth suppression could also be caused by inhibition of IGF-I levels, since Kovacs et al ( 1996) showed that chronic administration of MZ-4-7 1 reduces serum IGF-I concentration in rats by 15%. High-affinity receptors for IGF-I were demonstrated in membranes of Dunning R-3327 AT-I tumours, but chronic treatment of rats with the GH-RH antagonist did not produce a significant increase of the concentration of IGF-I receptors.
Our study shows that, in androgen-independent prostate cancer models, GH-RH antagonist MZ-4-71 can inhibit tumour growth and reduce serum IGF-I levels. Moreover, tumour tissue IGF-I and -II concentrations were decreased in the human PC-3 and DU-145 cell lines. If similar effects can be achieved in men, GH-RH antagonists might be considered for the development of new approaches to the treatment of patients with prostatic carcinoma who have relapsed following conventional androgen deprivation treatment. ABBREVIATIONS GH, growth hormone; GH-RH, growth hormone-releasing hormone; IGF-I, insulin-like growth factor-I; IGF-II, insulin-like growth factor-II; IGFR, insulin-like growth factor receptor; EGF, epidermal growth factor; LH-RH, luteinizing hormone-releasing hormone; TGF-a and -3, transforming growth factor-oc and -,B; DMSO: dimethyl sulphoxide.
